Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
复制标题
美国炭疽疫苗的使用：免疫实践咨询委员会 (ACIP) 的建议，2009 年。
DOI：
--
复制
发表时间：
2010
影响因子：
33.7
通讯作者：
Nancy E. Messonnier
中科院分区：
文献类型：
--
作者：
Jennifer G. Wright;C. Quinn;S. Shadomy;Nancy E. Messonnier
免疫实践咨询委员会（ACIP）的这些建议更新了以前关于吸附炭疽疫苗（AVA） （CDC）的建议。在美国使用炭疽疫苗：免疫实践咨询委员会[ACIP]的建议。MMWR 49:1-20; 2000;疾病预防控制中心。使用炭疽疫苗应对恐怖主义：免疫做法咨询委员会的补充建议。MMWR 2002;51:1024-6)，反映了美国炭疽疫苗供应的状况。本声明1)提供炭疽流行病学的最新资料；2)总结AVA的有效性、免疫原性和安全性方面的证据；3)提供事件前和暴露前使用AVA的建议；4)为暴露后AVA的使用提供建议。在某些情况下，没有改变的建议得到澄清。没有新的获得许可的炭疽疫苗。这些建议的重大变化包括：1)将完成事件前和暴露前初级系列所需的剂量从6剂减少到5剂；2)建议暴露前使用AVA肌肉注射而不是皮下注射；3)建议暴露于炭疽芽孢杆菌雾化孢子的孕妇使用AVA作为暴露后预防的组成部分。4)在职业健康规划的指导下，为应急和其他应急组织提供暴露前疫苗接种指导；5)建议在接触炭疽芽孢杆菌雾化后，结合3剂AVA进行60天的抗菌预防，以最佳地保护先前未接种疫苗的人员。
These recommendations from the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations for anthrax vaccine adsorbed (AVA) (CDC. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2000;49:1-20; CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2002;51:1024-6) and reflect the status of anthrax vaccine supplies in the United States. This statement 1) provides updated information on anthrax epidemiology; 2) summarizes the evidence regarding the effectiveness and efficacy, immunogenicity, and safety of AVA; 3) provides recommendations for pre-event and preexposure use of AVA; and 4) provides recommendations for postexposure use of AVA. In certain instances, recommendations that did not change were clarified. No new licensed anthrax vaccines are presented. Substantial changes to these recommendations include the following: 1) reducing the number of doses required to complete the pre-event and preexposure primary series from 6 doses to 5 doses, 2) recommending intramuscular rather than subcutaneous AVA administration for preexposure use, 3) recommending AVA as a component of postexposure prophylaxis in pregnant women exposed to aerosolized Bacillus anthracis spores, 4) providing guidance regarding preexposure vaccination of emergency and other responder organizations under the direction of an occupational health program, and 5) recommending 60 days of antimicrobial prophylaxis in conjunction with 3 doses of AVA for optimal protection of previously unvaccinated persons after exposure to aerosolized B. anthracis spores.
儿童分枝杆菌感染和疾病的管理。
DOI：
10.1097/00006454-199506000-00001
发表时间：
1995
期刊：
The Pediatric infectious disease journal
影响因子：
--
作者：
Starke,JR;Correa,AG
通讯作者：
Correa,AG